Covered recipient · General Payments record
CASSANDRA K PIERCE
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2023–2024
$710.55
- Reported across 41 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $583.33 | 34 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $232.68 | 14 |
| Lilly USA, LLC | $80.69 | 5 |
| PFIZER INC. | $72.85 | 4 |
| Acerta Pharma LLC | $69.78 | 4 |
| Novo Nordisk AS | $37.35 | 2 |
| Otsuka America Pharmaceutical, Inc. | $21.02 | 1 |
| EISAI INC. | $19.27 | 1 |
| Mylan Specialty L.P. | $18.63 | 1 |
| Exact Sciences Corporation | $16.80 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $14.26 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 2023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.15 | 01/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107850223 | CMS |
| ABBVIE INC. | $13.71 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107850225 | CMS |
| ABBVIE INC. | $20.31 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107850227 | CMS |
| ABBVIE INC. | $20.02 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107850229 | CMS |
| ABBVIE INC. | $24.32 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107850231 | CMS |
| ABBVIE INC. | $14.45 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107850233 | CMS |
| ABBVIE INC. | $25.31 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107850235 | CMS |
| ABBVIE INC. | $14.90 | 08/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107850237 | CMS |
| ABBVIE INC. | $23.42 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107850239 | CMS |
| ABBVIE INC. | $8.66 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107850241 | CMS |
| ABBVIE INC. | $18.03 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107850243 | CMS |
| ABBVIE INC. | $15.79 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107850245 | CMS |
| ABBVIE INC. | $8.11 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107850247 | CMS |
| ABBVIE INC. | $6.50 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107850249 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.02 | 02/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110552804 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.98 | 06/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110548458 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.07 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110534752 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.71 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110544261 | CMS |
| Eisai Inc. | $19.27 | 12/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110796839 | CMS |
| Exact Sciences Corporation | $16.80 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1128381367 | CMS |
| Lilly USA, LLC | $16.48 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135618817 | CMS |
| Lilly USA, LLC | $15.50 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135581212 | CMS |
| Lilly USA, LLC | $16.21 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135555644 | CMS |
| Lilly USA, LLC | $13.30 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135586815 | CMS |
| Lilly USA, LLC | $19.20 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135591726 | CMS |
| Mylan Specialty L.P. | $18.63 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147371896 | CMS |
| Novartis Pharmaceuticals Corporation | $14.26 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087330533 | CMS |
| Novo Nordisk Inc | $21.13 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108572154 | CMS |
| Novo Nordisk Inc | $16.22 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108570506 | CMS |
| Otsuka America Pharmaceutical, Inc. | $21.02 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119163166 | CMS |
| PFIZER INC. | $19.61 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130994851 | CMS |
| PFIZER INC. | $18.02 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131783970 | CMS |
| PFIZER INC. | $15.03 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131767792 | CMS |
| PFIZER INC. | $20.19 | 10/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132110695 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.